Finch Therapeutics Group Balance Sheet Health
Financial Health criteria checks 3/6
Finch Therapeutics Group has a total shareholder equity of $19.0M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $50.1M and $31.1M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
| Interest coverage ratio | n/a |
| Cash | US$20.76m |
| Equity | US$19.04m |
| Total liabilities | US$31.05m |
| Total assets | US$50.09m |
Recent financial health updates
Recent updates
Finch to cut workforce by about 37% after Takeda ends bowel disease collaboration
Sep 01Finch to get back rights to IBD product candidates after Takeda ends collaboration
Aug 25Finch Therapeutics GAAP EPS of -$0.48 misses by $0.07, revenue of $0.36M
Aug 11Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation
Mar 15
Here's Why We're Watching Finch Therapeutics Group's (NASDAQ:FNCH) Cash Burn Situation
Dec 15We Think Finch Therapeutics Group (NASDAQ:FNCH) Needs To Drive Business Growth Carefully
Aug 28Finch Therapeutics: Gut Instinct Says Buy
Jun 14Financial Position Analysis
Short Term Liabilities: FNCH's short term assets ($21.2M) exceed its short term liabilities ($3.5M).
Long Term Liabilities: FNCH's short term assets ($21.2M) do not cover its long term liabilities ($27.6M).
Debt to Equity History and Analysis
Debt Level: FNCH is debt free.
Reducing Debt: FNCH had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: FNCH has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: FNCH has less than a year of cash runway if free cash flow continues to grow at historical rates of 0.8% each year.